One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2021-148078
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 57 |
Affiliation: Dana-Farber Cancer Institute, University of California, Los Angeles, Karmanos Cancer Institute, Wayne State University, Mayo Clinic, Vanderbilt University, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, University of Iowa, Moffitt Cancer Center, Cleveland Clinic, City Of Hope National Medical Center, University of Rochester, Sarah Cannon, Tennessee Oncology, University of Miami Health System, Sylvester Comprehensive Cancer Center, Stanford University, Loyola University Chicago, Hackensack University Medical Center
Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
